These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26065532)

  • 21. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
    Vanhuyse M; Kluza J; Tardy C; Otero G; Cuevas C; Bailly C; Lansiaux A
    Cancer Lett; 2005 Apr; 221(2):165-75. PubMed ID: 15808402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin.
    Gao A; Wang X; Xiang W; Liang H; Gao J; Yan Y
    J Pharm Pharmacol; 2010 Mar; 62(3):393-9. PubMed ID: 20487225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells.
    Liu R; Zhang Y; Chen Y; Qi J; Ren S; Xushi MY; Yang C; Zhu H; Xiong D
    J Pharm Sci; 2010 Jul; 99(7):3266-75. PubMed ID: 20112430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro.
    Gurjar R; Chan CYS; Curley P; Sharp J; Chiong J; Rannard S; Siccardi M; Owen A
    Mol Pharm; 2018 Nov; 15(11):4835-4842. PubMed ID: 30350641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.
    Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN
    Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.
    Lo YL
    J Control Release; 2003 Jun; 90(1):37-48. PubMed ID: 12767705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Ji BS; He L; Liu GQ
    Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic.
    Ma B; Chai S; Li N; To KK; Kan WL; Yang D; Lin G
    Int J Pharm; 2012 Mar; 424(1-2):33-9. PubMed ID: 22226881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
    Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
    J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
    Khdair A; Handa H; Mao G; Panyam J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
    Zaja R; Caminada D; Loncar J; Fent K; Smital T
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
    Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
    Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
    Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
    FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells.
    Dash TK; Konkimalla VSB
    J Pharm Pharmacol; 2017 Jul; 69(7):834-843. PubMed ID: 28397291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein.
    Bohácová V; Sulová Z; Dovinová I; Poláková E; Barancík M; Uhrík B; Orlický J; Breier A
    Toxicol In Vitro; 2006 Dec; 20(8):1560-8. PubMed ID: 16962737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1.
    Wesołowska O; Wiśniewski J; Sroda K; Krawczenko A; Bielawska-Pohl A; Paprocka M; Duś D; Michalak K
    Eur J Pharmacol; 2010 Oct; 644(1-3):32-40. PubMed ID: 20633549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
    Shi R; Li W; Zhang X; Zhang Y; Peng H; Xie Y; Fan D; Liu R; Liu X; Xiong D
    Eur J Pharmacol; 2011 Nov; 669(1-3):38-44. PubMed ID: 21871878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.